Skip to main content
. 2018 Oct 20;37:344–355. doi: 10.1016/j.ebiom.2018.10.019

Fig. 2.

Fig. 2

High-throughput screening with the FDA-approved drug library. (a) Schematic view of the screening strategy. Cpd, compoud. (b) Analysis of the relative GFP intensity change upon isoproterenol treatment in the screening. (n = 15 for each treatment). (c) Screening results displaying relative GFP intensity of individual compounds. Representative compounds that led to increased GFP intensity were highlighted in Red, and that led to decreased GFP intensity were highlighted in Blue. (n = 3 for each treatment). (d) mRNA expression analysis of genes in sutent, isoproterenol or DMSO -treated Ucp1-2A-GFP brown adipocytes. (n = 3 for each treatment). (e) Western blot analysis of UCP1 protein expression in sutent or DMSO -treated Ucp1-2A-GFP brown adipocytes. (n = 2 for each treatment). Data are represented as means with SD. * P < 0.05, ** P < 0.01 (one-way ANOVA test and post-hoc Bonferronic multiple comparison test).